[1]王鑫,陈光伟,杨洋,等.扶正抗癌方合柴芍六君子汤联合贝伐珠单抗+FOLFOX方案治疗转移性结直肠癌[J].现代中医药,2020,(06):070-76.[doi:10.13424/j.cnki.mtcm.2020.06.017]
　Wang Xin,Chen Guangwei,Yang Yang,et al.Fuzheng Anticancer Formula and Chaishao Liujunzi Decoction Combined with Bevacizumab + FOLFOX Regimen in the Treatment of Metastatic Colorectal Cancer[J].Modern Traditional Chinese Medicine,2020,(06):070-76.[doi:10.13424/j.cnki.mtcm.2020.06.017]
点击复制

扶正抗癌方合柴芍六君子汤联合贝伐珠单抗+FOLFOX方案治疗转移性结直肠癌()
分享到：

《现代中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2020年06期
页码:
070-76
栏目:
出版日期:
2023-11-20

文章信息/Info

Title:
Fuzheng Anticancer Formula and Chaishao Liujunzi Decoction Combined with Bevacizumab + FOLFOX Regimen in the Treatment of Metastatic Colorectal Cancer
文章编号:
1672-0571(2020)06-0070-07
作者:
王鑫1; 陈光伟1; 杨洋2; 刘追星2
1.陕西中医药大学附属医院,陕西咸阳712000;
2.西安国际医学中心肿瘤医院,陕西西安710100
Author(s):
Wang Xin 1;  Chen Guangwei 1;  Yang Yang 2;  Liu Zhuixing 2
1. The Affiliated Hospital of Shaanxi University ofChinese Medicine, Xianyang Shaanxi, 7120002;
2. Tumor Hospital of Xi’an International Medical Center, Xi’an Shaanxi, 710100
关键词:
扶正抗癌方; 柴芍六君子汤; 贝伐珠单抗; FOLFOX方案; 肝郁脾虚证; 转移性结直肠癌
Keywords:
Fuzheng Anticancer Decoction;  Chaishao Liujunzi Decoction;  Bevacizumab;  FOLFOX Regimen;  liver stagnation and spleen deficiency;  Metastatic Colorectal Cancer
分类号:
R273
DOI:
10.13424/j.cnki.mtcm.2020.06.017
文献标志码:
A
摘要:
目的观察扶正抗癌方合柴芍六君子汤联合贝伐珠单抗+FOLFOX方案治疗转移性结直肠癌的临床疗效?方法回顾性分析2016年7月-2018年12月中医辨证为肝郁脾虚证的mCRC患者53例?按既往治疗方案不同,分为对照组26例,采用贝伐珠单抗+FOLFOX方案化疗;治疗组27例,采用贝伐珠单抗+FOLFOX方案化疗的同时配合口服扶正抗癌方合柴芍六君子汤治疗?比较两组患者的客观缓解率(ORR),疾病控制率(DCR)?无进展生存期(PFS)?不良反应发生率及临床症状改善率?结果治疗组患者的ORR和DCR较对照组明显提高,差异具有统计学意义(P<0.05)?治疗组患者的中位无进展生存时间(mPFS)为(12.60±0.74)个月(95%CI:11.15~14.05个月),对照组患者的中位无进展生存时间(mPFS)为(10.40±0.70)个月(95%CI:9.03~11.78个月),差异具有统计学意义(χ2=6.63,P=0.01)?在治疗过程中,治疗组患者出现恶心?呕吐?白细胞减少?血小板减少,色素沉着?感觉神经毒性等毒性反应的发生率要显著低于对照组,差异具有显著统计学意义(P<0.05)?且治疗组对肝郁脾虚型mCRC患者食少纳呆?脘闷不适?腹胀及便溏不爽等临床症状改善方面整体优于对照组,差异具有统计学意义(P<0.05)?结论扶正抗癌方合柴芍六君子汤联合贝伐珠单抗+FOLFOX方案治疗肝郁脾虚证mCRC患者,可以显著提高患者的ORR?DCR?PFS?减轻化疗毒副反应及改善患者的生活质量?
Abstract:
Objective To observe the clinical effect of Fuzheng Anticancer Decoction and Chaishao Liujunzi Decoction ( ingrediants include ginseng, atractylodes rhizome, tuckahoe, orange peel, pinellia ternata ( ginger) , liquorice root, bupleurum root, white peony root, rattan hook) combined with bevacizumab + FOLFOX regimen in the treatment of metastatic colorectal cancer. Methods A retrospective analysis of 53 cases of mCRC patients diagnosed as liver stagnation and spleen deficiency according to TCM syndrome differentiation ranging from July 2016 to December 2018. According to the previous treatment plan, they were divided into control group with 26 cases and given bevacizumab + FOLFOX regimen chemotherapy; 27 cases in the treatment group were treated with bevacizumab + FOLFOX regimen chemotherapy plus oral Fuzheng Anticancer formula and Chaishao Liujunzi Decoction. The objective response rate ( ORR) , disease control rate ( DCR) , progression - free survival ( PFS) , adverse reaction rate and clinical symptom improvement rate of the two groups were compared. Results The ORR and DCR of the treatment group were significantly higher than those of the control group, and the difference was statistically significant ( P < 0. 05) . The median progression - free survival time ( mPFS) of patients in the treatment group was 12. 60 ±0. 74 months ( 95% CI: 11. 15 -14. 05 months) , and the median progression - free survival time ( mPFS) of patients in the control group was 10. 40 ±0. 70 months ( 95% CI: 9. 03 -11. 78 months) , the difference was statistically significant ( χ2 =6. 63, P =0. 01) . During the course of treatment, the incidence of toxic reactions such as nausea, vomiting, leukopenia, thrombocytopenia, pigmentation, and sensory neurotoxicity in the treatment group were significantly lower than those in the control group, and the difference was statistically significant ( P <0. 05) . In addition, the treatment group was better than the control group in improving the clinical symptoms of mCRC patients with liver depression and spleen deficiency , such as anorexia, discomfort in stomach, abdominal distension and uncomfortable stools, and the difference was statistically significant ( P <0. 05) . Conclusion Fuzheng Anticancer Formula combined with Chaishao Liujunzi Decoction combined with bevacizumab + FOLFOX regimen in the treatment of mCRC patients with liver stagnation and spleen deficiency can significantly improve the patients’ ORR, DCR,PFS, reducing the side effects of chemotherapy and improving the quality of patients’ life .

参考文献/References:

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA: a Cancer Journal for Clinicians, 2017,67(1): 7-30.
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J] . CA: ACancer Journal for Clinicians,2018,68(6):394-424.
[3] Shafiee M, Aleyasin SA, Vasei M, et al. Down – regulatory effects of miR-211 on long non-coding RNA SOX2OT and SOX2 genes in esophageal squamous cell carcinoma[J] . Cell,2016,17(4):593-600.
[4]余伟.转移性结直肠癌一线全身治疗方案疗效评价的网状meta分析[D].重庆:重庆医科大学,2019.
[5] Messersmith, Wells A.Systemic Management of Colorectal Cancer [J]. Journal of the National Comprehensive Cancer Network Jnccn,2017,15(5S):699.
[6]谢永铮,任学群.贝伐珠单抗联合FOLFOX治疗晚期转移性结直肠癌的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(22):2208-2210.
[7]陈光伟,殷群,吕予.恶性肿瘤转移中医防治浅析[J].陕西中医,2011,32(5):638-639.
[8]]杨越,刘宁宁,张程程,等.大肠癌转移的中医病机探讨[J].中华中医药学刊,2018,36(9):2214-2216.
[9]刘平,李雁,徐静,等.扶正祛邪治则在大肠癌治疗中的应用[J].现代中西医结合杂志,2019,28(15):1692-1696.
[10] Hashiguchi Y, Muro k, Saito Y, etal. Japanese Societg for Cancer of the Colon and Retecturm (JSCCR) guidelines 2019 for the treatment for the treatment of colorectal cancer[J]. Int J Chin Oncol ,2020,25(1):1-42.
[11]马聪明.疏木扶土方治疗结直肠癌术后肝郁脾虚型肠郁的临床研究[D].昆明:云南中医药大学,2019.
[12]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:362.
[13] Morse B, Jeong D, Ihnat G, et al. Pearls and pitfalls of response evaluation criteria in solid tumors (RECIST) v1. 1non-target lesion assessment[J]. Abdominal Radiology,2019,44(2):766-774.
[14] Price T, Shen L, Ma B, et al. Phase II APEC trial: The impact of primary tumor side on outcomes of first - linecetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer[J]. Asia–Pacific Journal of Clinical Oncology,2019,15(4):225-230.
[15] Elferink MAG, Jong KP, Klaase JM, et al. Metachronous metastases from colorectal cancer: a population – based study in North-East Netherlands[J]. International Journal of Colorectal Disease,2015,30(2):205-212.
[16]梁芳,袁旭,于宏杰,等.基于“虚”本质的大肠癌辨证论治方法探索[J].辽宁中医杂志,2018,45(4):722-725.
[17]史碧霄,曹云,李?.归芍六君子汤加减辅助化疗治疗大肠癌肝转移25例临床研究[J].江苏中医药,2018,50(12):36-38.
[18]谭硕果,梁永艺.半夏泻心汤联合mFOLFOX6方案治疗晚期结肠癌[J].深圳中西医结合杂志,2019,29(22):25-26.
[19]王方杰.不同时机中医补益法协同化疗抗结肠癌的有效性分析[J].中医临床研究,2014,6(8):91-92.
[20] Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer[J]. The New England Journal of Medicine,2004,350(23):2335-2342.
[21]秦叔逵,邓艳红,毕锋,等.贝伐珠单抗联合含氟尿嘧啶类化疗方案治疗晚期转移性结直肠癌的前瞻性?非干预性?全国多中心临床研究(REACT)[J].临床肿瘤学杂志,2016,21(10):865-873.
[22]孙瑞华,蔡新生.中医药对大肠癌的精准治疗及研究进展[J].陕西中医,2019,40(11):1653-1656.

相似文献/References:

[1]刘 玲.柴芍六君子汤加减治疗慢性胃炎疗效观察[J].现代中医药,2019,(05):075.[doi:10.13424/j.cnki.mtcm.2019.05.023]

备注/Memo

备注/Memo:
基金项目:陕西省科技厅重点研发计划一般项目(2018SF-309);咸阳市科学技术局科技成果推广计划项目(2018KT-23)
通讯作者:杨洋,主治医师?E-mail:doctoryang1985@163.com
更新日期/Last Update: 2020-11-26